{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:48:32Z","timestamp":1788400112243,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1016\/j.pnpbp.2003.10.010","type":"journal-article","created":{"date-parts":[[2003,12,9]],"date-time":"2003-12-09T11:55:53Z","timestamp":1070970953000},"page":"311-318","source":"Crossref","is-referenced-by-count":21,"title":["Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia"],"prefix":"10.1016","volume":"28","author":[{"given":"Martin R.K","family":"Dossenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Folnegovic-Smalc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljubomir","family":"Hotujac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borben","family":"Uglesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D","family":"Tollefson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Starr L","family":"Grundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Friedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav Miro","family":"Jakovljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2003.10.010_BIB1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00004850-199609000-00001","article-title":"Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they \u201cstabilizers\u201d rather than typical compounds?","volume":"11","author":"Altamura","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB2","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/schbul\/19.3.609","article-title":"Subjective response to neuroleptics in schizophrenia","volume":"19","author":"Awad","year":"1993","journal-title":"Schizophr. Bull."},{"issue":"Suppl. 2","key":"10.1016\/j.pnpbp.2003.10.010_BIB4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00004850-199605002-00009","article-title":"Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome","volume":"11","author":"Awad","year":"1996","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.174.1.23","article-title":"Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol","author":"Beasley","year":"1999","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.jcp.0000095348.32154.ec","article-title":"A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse","volume":"23","author":"Beasley","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl. 11","key":"10.1016\/j.pnpbp.2003.10.010_BIB8","first-page":"40","article-title":"Side effect profiles of new antipsychotic agents","volume":"57","author":"Casey","year":"1996","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.pnpbp.2003.10.010_BIB9","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/S0924-977X(97)88650-6","article-title":"Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial","volume":"7","author":"Crawford","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB10","first-page":"1571","article-title":"Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia","volume":"4","author":"Dellva","year":"1997","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB11","first-page":"222","article-title":"The hillside akathisia scale: a new rating instrument for neuroleptic-induced akathisia","volume":"25","author":"Fleischhacker","year":"1989","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB12","series-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy","year":"1976"},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychol. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2003.10.010_BIB14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00023210-199600051-00004","article-title":"Compliance and outcome in patients treated with antipsychotics: the impact of extrapyramidal syndromes","volume":"5","author":"Hummer","year":"1996","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB15","first-page":"3","article-title":"Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia","volume":"11","author":"Jakovljevic","year":"1999","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB16","series-title":"Positive and Negative Syndrome Scale (PANSS) manual","author":"Kay","year":"1986"},{"issue":"Suppl. 3","key":"10.1016\/j.pnpbp.2003.10.010_BIB17","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/00004850-199803003-00007","article-title":"Good medical practice in antipsychotic pharmacotherapy","volume":"13","author":"Peuskens","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB18","first-page":"25","article-title":"Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study","volume":"29","author":"Sacristan","year":"2001","journal-title":"Actas Esp. Psiquiatr."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB20","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB22","first-page":"457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.v58n0505","article-title":"Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia","volume":"58","author":"Tran","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2003.10.010_BIB24","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1192\/bjp.172.6.499","article-title":"Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses","volume":"172","author":"Tran","year":"1998","journal-title":"Br. J. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584603002604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584603002604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T10:26:45Z","timestamp":1550312805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584603002604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0278584603002604"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2003.10.010","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}